Celltrion rises 11.55% amid uptrend in biosimilar (biologic drug copy) theme

On the 11th, the biosimilar (generic biopharmaceutical) theme showed strength, rising 3.08% compared to the previous day, with Celltrion, a related stock drawing attention, soaring 11.55% from the previous day. Celltrion is known as a protein and biopharmaceutical manufacturing company.

[Graph] Major stock price changes in the biosimilar (generic biopharmaceutical) theme



According to provisional data compiled at 11:26, Celltrion is experiencing large net selling by institutions, with institutions selling 33,000 shares.

[Table] Net trading volume by foreigners and institutions (unit: 10,000 shares)



According to the analysis by Thinkpool Robo Algorithm RASSI, Celltrion’s quant financial score is 38.5 points, ranking 8th within the biosimilar (generic biopharmaceutical) theme, with higher stability and profitability scores compared to the average of other related stocks. This indicates that, from a financial perspective, Celltrion’s ability to respond to internal and external economic environment changes and its efficient profit-generating capacity are better than those of other stocks in the theme.

[Table] Top stocks by financial score within the theme


※ The quant financial score is the result of analysis by the Robo Algorithm based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.